GLP1R and metabolic dysfunction-associated steatotic liver disease: Altogether, these trials highlight the potential of dual GLP-1/glucagon receptor agonists in treating MASLD through complementary mechanisms that reduce liver fat, improve cardiometabolic markers, and address liver inflammation.